

RESEARCH



Co-introduction of plasmids harbouring the carbapenemase genes, *bla*_{NDM-1} and *bla*_{OXA-232}, increases fitness and virulence of bacterial host



Haejeong Lee¹, Juyoun Shin², Yeun-Jun Chung^{2,3}, Myungseo Park⁴, Kyeong Jin Kang⁵, Jin Yang Baek⁶, Dongwoo Shin¹, Doo Ryeon Chung^{6,7}, Kyong Ran Peck⁷, Jae-Hoon Song⁶ and Kwan Soo Ko^{1,6*}

Abstract

Background: Bacterial isolates with multiple plasmids harbouring different carbapenemase genes have emerged and been identified repeatedly, despite a general notion that plasmids confer fitness cost in bacterial host. In this study, we investigated the effects of plasmids with carbapenemase genes on the fitness and virulence of bacteria.

Methods: Different plasmids harbouring the carbapenemase genes, bla_{NDM-1} and $bla_{OXA-232}$, were isolated from a carbapenem-resistant *K. pneumoniae* strain. Each plasmid was conjugated into the *Escherichia coli* strain DH5 α , and a transconjugant with both plasmids was also obtained by transformation. Their in vitro competitive ability, biofilm formation, serum resistance, survival ability within macrophage and fruit fly, and fly killing ability were evaluated.

Results: The transconjugants with a single plasmid showed identical phenotypes to the plasmid-free strain, except that they decreased fly survival after infection. However, significantly increased fitness, virulence and biofilm production were observed consistently for the transconjugant with both plasmids, harbouring *bla*_{NDM-1} and *bla*_{OXA-232}.

Conclusions: Our data indicate that bacteria carrying multiple plasmids encoding different carbapenemases may have increased fitness and virulence, emphasizing the need for diverse strategies to combat antimicrobial resistance.

Keywords: Carbapenemase, NDM-1, OXA-232, Plasmid, Plasmid paradox

Introduction

Carbapenems are antibiotics used for the treatment of severe infections caused by multidrug resistant gram-negative pathogens [1]. However, carbapenem-resistant isolates have emerged as important causes of morbidity and mortality, among hospital-acquired and long-term care-associated infections [2]. Particularly, the carbapenemase-producing *K. pneumoniae* isolates have become a public health problem globally due to their transmission mechanism and the limited therapeutic options available [1, 3].

Full list of author information is available at the end of the article



In addition to *K. pneumoniae* carbapenemase (KPC), the New Delhi metallo- β -lactamase (NDM) and class D oxacillinases (OXA)-48 group carbapenemases are becoming the main causes underlying carbapenem resistance in *K. pneumoniae* [4, 5]. Since the first report in 2009 [6], NDM-1 and its variants have been identified in various bacterial species worldwide [7]. OXA-48 carbapenemases were initially identified in Istanbul, Turkey in 2001 [8, 9]. OXA-232, a variant of OXA-48, was first reported in an *E. coli* and two *K. pneumoniae* [10].

Recently, *K. pneumoniae* strains co-producing NDM-1 and OXA-232 have been reported in several countries [11–13]. In the strains, the $bla_{\text{NDM-1}}$ and $bla_{\text{OXA-232}}$ genes are in different plasmids [14]. Compared to the plasmid bearing $bla_{\text{NDM-1}}$, the plasmid with $bla_{\text{OXA-232}}$, a ColE-type plasmid, is very small (about 6000 bp) [14]. The associations between small and large plasmids are

© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: ksko@skku.edu

¹Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea

 $^{^{6}\}mbox{Asia}$ Pacific Foundation for Infectious Diseases (APFID), Seoul 06351, Republic of Korea

common across a wide range of bacterial phyla [15]. Hence, positive epistasis between co-infecting plasmids minimizes the cost associated with carrying multiple plasmids in bacterial populations [15].

In this study, we investigated the contributions of the single or dual presence of plasmids bearing $bla_{\text{NDM-1}}$ and $bla_{\text{OXA-232}}$ on the fitness and virulence in bacteria, using the plasmids from a *K. pneumoniae* strain isolated from the blood sample of a patient in a Korean hospital.

Materials and methods

Bacterial strains and plasmids

A K. pneumoniae strain, M5, co-producing NDM-1 and OXA-232 was obtained from the blood sample of a patient, a 53-year-old man, who underwent liver transplantation for hepatocellular carcinoma, in Samsung Medical Centre (Seoul, South Korea). The strain M5 belongs to sequence type 14. Three plasmids with sizes of 253 kb (pKPM501), 250 kb (pM5_NDM), and 6 kb (pM5_OXA) were identified. The whole sequences were determined through next-generation sequencing method with PacBio RSII platform and de novo assembly was done with bioinformatics softwares (HGAP3, FALCON, and CANU) [16]. The plasmids containing bla_{NDM-1} (pM5_NDM) and $bla_{OXA-232}$ (pM5_OXA) were transferred from the K. pneumoniae isolate M5 to the streptomycin-resistant (STR^R) E. coli DH5α as a recipient. Conjugation mixtures were incubated overnight at 37 °C and plated on selective agar, resulting in two transconjugants, namely, DH5α::pM5_NDM and DH5α:: pM5_OXA. Next, pM5_OXA was extracted from the transconjugant DH5a::pM5_OXA using a Qiagen Plasmid Mini kit (Qiagen, Hilden, Germany) and transformed into DH5 α ::pM5_NDM by electroporation [17], resulting in a transconjugant having two plasmids concurrently, DH5α::pM5_NDM + pM5_OXA. The three successful transconjugants, namely, DH5a::pM5_NDM, DH5a::pM5_OXA, and DH5a::pM5_NDM + pM5_OXA, were selected by plating onto MacConkey agar containing 0.25 mg/L of meropenem and 200 mg/L of streptomycin, and further confirmed by PCR with the primers for *bla*_{NDM-1} (forward, 5'-GGTTTGGCGATCTGGTTT TC-3' and reverse, 5'-CGGAATGGCTCATCACGATC-3') and *bla*_{OXA-232} (forward, 5'- GGCTGTGTTTTGG TGGCAT-3' and reverse, 5'-CGGTCAGCATGGCT TGTTTC-3'). In addition, we confirmed the absence of IncFIB plasmid with *bla*_{CTX-M-15} by PCR with the primers (forward, 5'-GCTGTCGCCCAATGCTTTAC-3' and reverse, 5'-GGCGGACGTACAGCAAAAAC-3').

Antimicrobial susceptibility testing

The minimum inhibitory concentrations (MICs) of 12 antimicrobial agents including imipenem, meropenem, cefotaxime, ceftazidime, ampicillin, gentamicin, amikacin, ciprofloxacin, tetracycline, trimethoprim-sulfamethoxazole, piperacillin-tazobactam, and colistin were determined using a broth microdilution method following the Clinical and Laboratory Standards Institute (CLSI) guidelines [18]. *E. coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as controls. All the tests were performed in duplicate, and each test included three biological replicates per strain.

Competition assay

To assess the impact of the plasmids on bacterial fitness, we determined the relative fitness of the transconjugants against the *E. coli* strain DH5 α . The competition assay was performed using a previously described method, with slight modifications [19]. The overnight cultures of the *E. coli* strain DH5 α and one of the three transconjugants were inoculated to obtain a 0.5 McFarland standard and mixed at a 1:1 ratio in 10 mL of LB both, and incubated at 37 °C for 24 h with shaking. The number of cells for each strain was determined by spreading serial 10-fold dilutions onto LB agar plates with or without 0.25 mg/L imipenem. The competition index (CI) was defined as the ratio of carbapenem-nonsusceptible transconjugant colony forming units (CFUs) to the *E. coli* strain DH5α CFUs. Five independent competition experiments were performed.

Biofilm formation assay

To measure the biofilm formation, 96-well microtiter plate assays were performed with crystal violet assay as described previously [20], with minor modifications. Briefly, the overnight bacterial cultures were diluted 1: 100 in 10 mL of fresh LB medium and incubated until the bacterial suspension reached an OD_{600} of 0.5. Two hundred millilitres of the adjusted bacterial cultures were transferred to 96-well polystyrene microtiter plates and were incubated for 24 h at 37 °C. The cells were washed twice with phosphate-buffered saline (PBS) and stained with 1% crystal violet for 20 min at room temperature. The wells were dried and the bound dye was solubilized with 200 µL of 95% ethanol and quantified by measuring the absorbance at 600 nm. A well containing sterile LB without bacteria served as the negative control. Each experiment was performed in duplicate and repeated five times.

Serum resistance assay

The serum resistance assays were performed as described previously [21]. Bacterial cultures were grown to mid-log phase (OD₆₀₀ of 0.5). Then, 1-mL aliquots of the cultures were washed and resuspended with PBS. Then, 100 μ L of the bacterial suspensions were added and mixed with 900 μ L of PBS containing 20% normal human serum (NHS, Innovative Research, MI, USA),

and the mixtures were incubated at 37 °C for 3 h with shaking. The number of surviving bacteria was determined by plating serial dilutions on agar plates and incubating at 37 °C overnight. Heat-inactivated human serum (HIS) was used as a control for determining the bactericidal effect of NHS. The survival rate was calculated as the ratio of the CFUs in the NHS to the CFUs in a bacterial suspension with HIS. All the experiments were performed five times and the results are expressed as survival percentage.

Survival inside macrophages

Intra-macrophage survival assays were conducted with the macrophage-like cell line J774 A.1 as described elsewhere [22] with slight modifications. Macrophage cells were grown in Dulbecco's modified Eagle's medium (DMEM, Welgene) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% antibiotic-antimycotic solution (Thermo). A monolayer of 1×10^6 J774A.1 cells was prepared in a 24-well tissue culture plate. After the cells were washed with Dulbecco's phosphate buffered saline (DPBS, Welgene) and incubated in DMEM with FBS for 1 h, the overnight incubated bacterial cells were added at a ratio of 20 bacteria per macrophage (MOI 20). The cells were incubated for 30 min at 37 °C to permit phagocytosis and the free bacteria were removed by three washes with DPBS. Then, the cells were incubated for 1 h in the pre-warmed medium supplemented with 150 µg of gentamicin/mL to kill extracellular bacteria, and the wells were washed and incubated in the medium with 15 µg of gentamicin/mL. For the 0-h timepoint sample, the wells were washed and treated immediately by aspirating the medium and adding 500 μ L of 1% Triton X-100 and 500 µL of DPBS. For the 4-h and 20-h time point samples, Triton X-100 was added at the desired time points. The content of each well was then diluted in DPBS and appropriate dilutions were plated on LB agar containing appropriate antibiotics. The percentage survival was obtained by dividing the number of bacteria recovered after 4 h and 20 h, by the number of bacteria present at time 0 and multiplying by 100. All the experiments were performed in duplicate.

Drosophila melanogaster (fruit fly) infection

Fly infection was performed by the thoracic needle pricking method as described [21, 23], with minor modifications. Briefly, *D. melanogaster* Canton Special was cultured on standard cornmeal agar medium at 26 °C. Fifteen female flies 3 to 5 days old were infected with bacterial cultures at $OD_{600} = 0.5$ with ultra-fine needle (BD Bioscience). A pure PBS injection was used as a negative control and the fly mortality was monitored for up to 72 h post-infection. For quantification of viable bacteria, the infected flies were collected at 48 h post-

infection, anesthetized with CO₂, and three flies per bacterial isolate were individually ground in 100 μ L of PBS with a Teflon pestle. Each resulting homogenate was serially diluted and plated onto LB agar containing appropriate antibiotics. The plates were incubated at 37 °C for 24 h and the number of CFU per fly was counted. Each experiment was performed four times.

Statistical analyses

Statistical analyses were performed using Prism version 3.00 for Windows (GraphPad Software, San Diego, CA). The differences were assessed using the Student's t-test, the one-way ANOVA with Tukey multiple comparisons test, and nonparametric Kruskal-Wallis test followed by Dunnett's multiple comparison test. *P* value of less than 0.05 was considered statistically significant (*, P < 0.05; **, P < 0.001; ***, P < 0.0001).

Accession numbers

The annotated sequences of pKPM501, pM5_NDM, and pM5_OXA have been submitted to the GenBank nucleotide sequence database (GenBank accession numbers CP031735, CP031736, and CP031737, respectively).

Results

Genetic characteristics of plasmids

The whole genome of strain M5 was sequenced using the PacBio RSII system, which identified 5,374,875 bp in the chromosome and three plasmids (pKPM501, IncFIB, 253,531 bp; pM5_NDM, IncHI/B, 250,351 bp; pM5_ OXA, ColKP3, 6141 bp). The bla_{NDM-1} and $bla_{OXA-232}$ carbapenemase genes were in two different plasmids, which were named as pM5_NDM and pM5_OXA. The G + C content of pM5_NDM was 46.4% and pM5_OXA was 52.2%. Their complete sequences were 250,351 bp and 6141 bp in length, with 283 and 7 coding genes, respectively (Table 1). Another plasmid, pKPM501, was 253,531 bp in length and had a G + C content of 51.2%, with 269 coding genes. While pM5_NDM bearing the bla_{NDM-1} gene also harboured additional antimicrobial resistance genes listed in Table 1, no other antimicrobial resistance gene except for the $bla_{OXA-232}$ was identified in the smallest plasmid, pM5_OXA. *bla*_{CTX-M-15}, an extended-spectrum β -lactamase gene, was identified in pKPM501.

Antimicrobial resistance

MICs of the transconjugants, a recipient, and their host strain were evaluated. The donor *K. pneumoniae* strain M5 co-producing NDM-1 and OXA-232 was not susceptible to most antibiotics except colistin (Table 2). As expected, the introduction of $bla_{\rm NDM-1}$ and $bla_{\rm OXA-232}$ genes in *E. coli* DH5 α conferred decreased susceptibility to carbapenems (imipenem and meropenem) (Table 2).

Table 1 The genetic features of the chromosome and three plasmids in the K. pneumoniae strain M5

	Chromosome	pKPM501	pM5 NDM	pM5 OXA
Size (bp)	5,374,875	253,531	250,351	6141
GC %	57.4	51.2	46.4	52.2
Plasmid Inc. group	_	IncFIB	IncHI/B	ColKP3
Coding sequences	4905	269	283	7
Antimicrobial resistance genes	bla _{OXA-1} bla _{SHV-28} aac(6')-lb-cr oqxB, oqxA fosA catB4 dfrA1	bla _{TEM-1} bla _{CTX-M-15} aac(6')-lb aac(6')-lb-cr catA1 dfrA14	bla _{NDM-1} bla _{OXA-1} aph(3')-Via armA, aadA2 aac(6')lb-cr catB4 dfrA12 mph(E), msr(E) sul1	bla _{OXA-232}

However, the carbapenem MICs in the transconjugants did not reach to the level of the donor. Particularly, DH5 α ::pM5_OXA showed imipenem and meropenem MICs of 1 mg/L and 0.25 mg/L, respectively. Moreover, the additional introduction of pM5_OXA into DH5 α :: pM5_NDM, resulting in a transconjugant with dual plasmids, did not increase the carbapenem MICs. Specifically, the imipenem MIC of DH5 α ::pNDM1 + pOXA232 was identical to that of DH5 α ::pNDM1 and the meropenem MIC increased two-fold, from 0.5 mg/L to 1 mg/L, which corresponds to susceptible category.

DH5α::pM5_NDM and DH5α::pM5_NDM + pM5_OXA were also resistant to cefotaxime, ceftazidime, ampicillin, gentamicin, amikacin, trimethoprim-sulfamethoxazole, and piperacillin-tazobactam, but susceptible to the other antibiotics including ciprofloxacin, tetracycline, and colistin. DH5α::pM5_OXA was susceptible to most antibiotics except ampicillin and piperacillin-tazobactam.

In vitro fitness

To investigate whether the propagation of plasmids harbouring $bla_{\text{NDM-1}}$ and $bla_{\text{OXA-232}}$ exhibit a fitness defect compared to the plasmid-free recipient strain, in vitro competition experiments were performed. In the media without antibiotics, the three plasmid-carrying transconjugants competed with the plasmid-free *E. coli* strain DH5 α (Fig. 1). The transconjugants with single plasmid (DH5 α ::pM5_NDM and DH5 α ::pM5_OXA) showed CI values of less than 1. The transconjugant with both the plasmids, DH5 α ::pM5_NDM + pM5_OXA, outcompeted the plasmid-free strain DH5 α (*P* < 0.0001) when analyzed with two tailed Student's t-test, showing a mean CI value of 9.95.

Biofilm formation and serum resistance

We performed biofilm formation assays on the recipient strain and three transconjugants (Fig. 2a). The transconjugant with pM5_NDM (DH5 α ::pM5_NDM) or pM5_OXA (DH5 α ::pM5_OXA) showed no difference in biofilm formation from the plasmid-free recipient strain DH5 α . However, the transconjugant with both the plasmids formed significantly more biofilm compared to the plasmid-free recipient and two transconjugants containing single plasmid when analyzed with the one-way ANOVA with Tukey multiple comparisons test.

Survival rates of the recipient strain and the transconjugants were evaluated in the presence of NHS over a 3 h period (Fig. 2b). DH5 α ::pM5_NDM and DH5 α ::pM5_ OXA showed no increase in the survival rates against human serum compared with the plasmid-free recipient

Table 2 Antimicrobial susceptibility profiles of the K. pneumoniae and E. coli strains used in this study

Strain	MIC (mg/L) (antimicrobial susceptibility category) ^{a, b}											
	IMI	MRP	CTX	CAZ	AMP	GEN	AMK	CIP	TET	SXT	P/T	CL
Donor (K. pneumoniae M5)	>64 (R)	>64 (R)	>128 (R)	>64 (R)	>64 (R)	>64 (R)	>128 (R)	>64 (R)	8 (I)	> 32/608 (R)	>256/4 (R)	0.5 (S)
Recipient (<i>E. coli</i> DH5a)	0.125 (S)	0.06 (S)	0.125 (S)	0.5 (S)	4 (S)	1 (S)	4 (S)	0.06 (S)	0.5 (S)	0.25/4.75 (S)	4/4 (S)	0.06 (S)
DH5a::pM5_NDM	4 (R)	0.5 (S)	>128 (R)	>64 (R)	>64 (R)	>64 (R)	>128 (R)	0.06 (S)	0.5 (S)	> 32/608 (R)	> 256/4 (R)	0.125 (S)
DH5a::pM5_OXA	1 (S)	0.25 (S)	4 (S)	0.5 (S)	>64 (R)	4 (S)	16 (S)	0.06 (S)	0.5 (S)	2/38 (S)	> 256/4 (R)	0.06 (S)
DH5a::pM5_NDM +pM5_OXA	4 (R)	1 (S)	>128 (R)	>64 (R)	>64 (R)	>64 (R)	> 128 (R)	0.06 (S)	0.5 (S)	> 32/608 (R)	> 256/4 (R)	0.06 (S)

^a*IMI* imipenem, *MRP* meropenem, *CTX* cefotaxime, *CAZ* ceftazidime, *AMP* ampicillin, *GEN* gentamicin, *AMK* amikacin, *CIP* ciprofloxacin, *TET* tetracycline, *SXT* trimethoprim-sulfamethoxazole, *P/T* piperacillin-tazobactam, *CL* colistin

^bR resistant, I intermediate-resistant, S susceptible

strain DH5 α . Only the transconjugant with both the plasmids, DH5α::pM5_NDM + pM5_OXA, exhibited a significantly higher survival rate against human serum than all the other strains (one-way ANOVA with Tukey multiple comparisons test, P < 0.05).

DHSG: ONS NON

OH50

А 0.5

OD 600 absorbance

0.4

0.3

0.2

0.1

0.0

Macrophage and fruit fly infection

Survival of plasmid-carrying transconjugants inside macrophage was evaluated (Fig. 3a). In the intramacrophage survival assay, the number of bacteria recovered after 4 h of infection (T4) did not differ among the four strains (one-way ANOVA, P > 0.05). However, after 20 h of infection (T20), DH5a::pM5_NDM and DH5a:: pM5 OXA, as well as DH5a, did not multiply in macrophage, but the survival rate of DH5α::pM5_NDM + pM5_ OXA was significantly higher (one-way ANOVA with Tukey multiple comparisons test, P, 0.0011).

We examined the survival rates of D. melanogaster against E. coli infections (Fig. 3b). The transconjugants with a single plasmid showed increased fly killing ability compared to the plasmid-free recipient strain DH5 α and the transconjugant with both the plasmids (DH5a::pM5_ NDM + pM5_OXA) showed a further increase in fly killing ability than those with a single plasmid. In addition, the number of viable bacteria isolates from flies after 48 h of infection was also measured (Fig. 3c). As in the experiment of fly killing, significantly more bacterial colonies survived in the flies infected with DH5α::pM5_NDM + pM5_OXA than the other strains (Kruskal-Wallis test followed by Dunnett's multiple comparison test, P < 0.05)

Discussion

В

Survival rate (%)

200

150

100

50

0

OHSO

DH50: PMS HOW

DHSS: 9NS OXA

It has been considered that plasmids generally impose a fitness cost on their bacterial hosts and thus, it is expected that they would not be retained in the cell in the absence of selective pressure. However, many studies have shown that plasmids can persist in bacterial populations over the long term, even in the absence of positive selection, which is referred to as the 'plasmid









paradox' [24]. In this study, we showed that the simultaneous presence of two plasmids harbouring different carbapenemase genes increased the fitness and virulence of a bacterial host, although a single plasmid did not.

Each plasmid bearing a carbapenemase gene from a carbapenem-resistant K. pneumoniae strain, when introduced individually, did not increase the resistance level in E. coli to that in K. pneumoniae. The introduction of a plasmid harbouring $bla_{OXA-232}$ did not impart carbapenem resistance comparable to that of the transconjugant with *bla*_{NDM-1}. Previously, it was reported that the carbapenemase OXA-232 did not increase the MIC in E. coli transconjugants, as opposed to their effect in K. pneumoniae [10, 25]. Although the third plasmid, for example, a plasmid with $bla_{CTX-M-15}$ in this study, may influence the fitness of the strain, this suggests that antibiotic resistance is determined by interactions between the resistance genes and bacterial host, and not by the existence of the resistance genes alone. In addition, it may also imply that the plasmid with carbapenemase gene can spread undetected, imparting resistance only under specific circumstances, such as in certain bacterial species and upon permeability defects in certain isolates [25].

One of the most interesting results in this study is that the transconjugant with both the plasmids showed increased fitness and virulence traits. Although many studies have shown that a single plasmid may increase fitness or virulence of the bacterial host [26-31], the transconjugants with a single plasmid did not in most tests in our study with the exceptions of reducing fly survival. In a previous study, the introduction of only *bla*_{NDM-1} did not increase the virulence or cytotoxicity in E. coli and K. pneumoniae transconjugants [20]. However, the E. coli strain with both plasmids, harbouring bla_{NDM-1} and bla_{OXA-232} which were isolated from a carbapenem-resistant K. pneumoniae strain, exhibited higher in vitro competitive ability, biofilm formation, serum resistance, and survival ability within macrophage and fruit fly, compared to transconjugants with a single plasmid. In addition, the transconjugant with both plasmids showed higher ability to kill fruit fly than those with a single plasmid as well as the parental strain with

no plasmid. The high fitness and virulence of the bacterial strain with dual plasmids were consistent in all the experiments.

San Millan et al. [15] have shown that co-infection of a large plasmid and a small plasmid invokes positive epistasis, minimizing the cost associated with carrying multiple plasmids. In our study, pM5_NDM is a relatively large plasmid (about 250 kb) and pM5_OXA is a small one (about 6 kb), indicating that the positive epistasis between the two plasmids might occur. Although it is unknown which plasmid was introduced into the *K. pneumoniae* strain first and which plasmid was conjugated into the same strain later, our results suggest that the co-introduction of two plasmids harbouring carbapenemase genes can cause synergistic effect on the survival and spread of bacterial hosts.

In this study, it was not clear why the introduction of dual plasmids harbouring the carbapenemase genes increased the fitness and virulence. Several studies have shown transcriptional changes in the chromosomal and plasmid genes, and metabolites due to the introduction of plasmids [30, 32, 33]. However, no general mechanism has been proposed, indicating that the fitness effects of plasmids may be due to complex interactions [34].

Strains carrying multiple plasmids are relatively common [15]. In nature, NDM-1 and OXA-232-co-producing isolates have been identified repeatedly [11, 12, 35, 36]. In addition to bla_{NDM-1} and $bla_{OXA-232}$, many isolates with multiple plasmids harbouring other antibiotic resistance genes have been reported [37, 38]. In addition, specific genes in the plasmid for instance, adhesion factors for biofilm formation, may affect the traits of the strain with plasmid, but we did not reveal which genes of plasmids affect the fitness or virulence traits, which would be further study. Because the fitness impact caused by plasmids may vary widely with different plasmids [28], the synergistic effect from the existence of dual plasmids bearing carbapenemase genes on survival, fitness, and virulence could not be generalized. However, our data suggest the possibility that bacterial strains with higher fitness and virulence traits would emerge and disseminate, due to the additional introduction of plasmid harbouring antibiotic resistance genes.

Conclusions

A transconjugant with both plasmids harbouring bla_{NDM-1} and $bla_{OXA-232}$, which originated from a carbapenemresistant *K. pneumoniae*, exhibited increased fitness and virulent traits in terms of in vitro competition index, biofilm formation, in vitro serum resistance, survival within macrophage, and killing effect of *D. melanogaster* and survival within it. These data indicate that carbapenemaseproducing gram-negative pathogens may disseminate even in the absence of antibiotic pressure and may cause more severe infections, emphasizing the need for diverse strategies to combat antimicrobial resistance.

Abbreviations

CFU: colony forming unit; CI: competition index; CLSI: Clinical and Laboratory Standards Institute; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; HIS: heat-inactivated human serum; KPC: *Klebsiella pneumoniae* carbapenemase; LB: Luria-Bertani; MIC: minimum inhibitory concentration; MOI: multiplicity of infection; NDM: New Delhi metallo-β-lactamase; NHS: norman human serum; OXA: oxacillinase; PBS: phosphate-buffered saline

Acknowledgements

The *K. pneumoniae* isolate included in this study was obtained from the Asian Bacterial Bank (ABB) of the Asia Pacific Foundation for Infectious Disease (APFID, Seoul, Korea).

Authors' contributions

HL, JS, and KSK designed the experiments. HL, JYB and MP performed the experiments. HL, JS, YJC, KGK, JYB and KSK analysed the data. DS, DRC, KRP and JHS provided resources and helped to design the experiments and to analyse the data. HL and KSK wrote the manuscript. All authors read and approved the final manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (grant NRF-2019R1A2C2004879).

Availability of data and materials

All materials are available by the corresponding author.

Ethics approval and consent to participate Not applicable.

not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea. ²Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. ³Precision Medicine Research Center, Integrated Research Center for Genome Polymorphism, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. ⁴Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon 16419, South Korea. ⁵Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea. ⁶Asia Pacific Foundation for Infectious Diseases (APFID), Seoul 06351, Republic of Korea. ⁷Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.

Received: 28 August 2019 Accepted: 19 December 2019 Published online: 03 January 2020

References

- 1. Nordmann P, Cuzon G, Naas T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.
- Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. Lancet Infect Dis. 2013;13:785–96.
- Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Group for the study of KPC-producing *Klebsiella pneumoniae* infections in intensive care units. Infections caused by carbapenem-resistant *Klebsiella pneumoniae* among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20:O117–23.

- Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18:263–72.
- Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707.
- Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-β-lactamase gene, *bla*_{NDM-1}, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54.
- Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Carbapenemaseproducing *Klebsiella pneumoniae*: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895.
- Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinasemediated resistance to imipenem in *Klebsiella pneumoniae*. Antimicrob Agents Chemother. 2004;48:15–22.
- Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012;67:597–1606.
- Potron A, Rondinaud E, Poirel L, Belmonte O, Boyer S, Camiade S, Nordmann P. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae. Int J Antimicrob Agents. 2013;41:325–9.
- Doi Y, O'Hara JA, Lando JF, Querry AM, Townsend BM, Pasculle AW, Muto CA. Co-production of NDM-1 and OXA-232 by *Klebsiella pneumoniae*. Emerg Infect Dis. 2014;20:163.
- Al-Marzooq F, Ngeow YF, Tay ST. Emergence of *Klebsiella pneumoniae* producing dual carbapenemases (NDM-1 and OXA-232) and 16S rRNA methylase (*armA*) isolated from a Malaysian patient returning from India. Int J Antimicrob Agents. 2015;45:445–6.
- Kwon T, Jung YH, Lee S, Yun MR, Kim W, Kim DW. Comparative genomic analysis of *Klebsiella pneumoniae subsp. pneumoniae* KP617 and PittNDM01, NUHL24835, and ATCC BAA-2146 reveals unique evolutionary history of this strain. Gut Pathog. 2016;8:34.
- Doi Y, Hazen TH, Boitano M, Tsai YC, Clark TA, Korlach J, Rasko DA. Whole genome assembly of *Klebsiella pneumoniae* co-producing NDM-1 and OXA-232 carbapenemases using single-molecule, real-time sequencing. Antimicrob Agents Chemother. 2014;AAC-03180.
- San Millan A, Heilbron K, MacLean RC. Positive epistasis between coinfecting plasmids promotes plasmid survival in bacterial populations. ISME J. 2014;8:601–12.
- Lee H, Shin J, Chung YJ, Baek JY, Chung DR, Peck KR, et al. Evolution of *Klebsiella pneumoniae* with mucoid and non-mucoid type colonies within a single patient. Int J Med Microbiol. 2019;309:194–8.
- Shin J, Ko KS. Single origin of three plasmids bearing *bla*_{CTX-M-15} from different *Klebsiella pneumoniae* clones. J Antimicrob Chemother. 2014;69: 969–72.
- Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: twenty-seventh informational supplement M100-S27. Wayne: CLSI; 2017.
- Kim J, Lee JY, Lee H, Choi JY, Kim DH, Wi YM, et al. Microbiological features and clinical impact of the type VI secretion system (T6SS) in *Acinetobacter baumannii* isolates causing bacteremia. Virulence. 2017;8:1378–89.
- Göttig S, Riedel-Christ S, Saleh A, Kempf VA, Hamprecht A. Impact of bla_{NDM-1} on fitness and pathogenicity of *Escherichia coli* and *Klebsiella* pneumoniae. Int J Antimicrob Chemother. 2016;47:430–5.
- Lee H, Baek JY, Kim SY, Jo H, Kang K, Ko JH, et al. Comparison of virulence between matt and mucoid colonies of *Klebsiella pneumoniae* coproducing NDM-1 and OXA-232 isolated from a single patient. J Microbiol. 2018;56: 665–72.
- Choi E, Kim H, Lee H, Nam D, Choi J, Shin D. The iron-sensing Fur regulator controls expression timing and levels of *Salmonella* pathogenicity island 2 genes in the course of environmental acidification. Infect Immun. 2014;82: 2203–10.
- Heo YJ, Lee YR, Jung HH, Lee J, Ko G, Cho YH. Antibacterial efficacy of phages against *Pseudomonas aeruginosa* infections in mice and *Drosophila melanogaster*. Antimicrob Agents Chemother. 2009;53:2474.
- 24. Harrison E, Brockhurst MA. Plasmid-mediated horizontal gene transfer is a coevolutionary process. Trends Microbiol. 2012;20:262–7.
- Yang S, Hermarajata P, Hindler J, Li F, Adisetiyo H, Aldrovandi G, et al. Evolution and transmission of carbapenem-resistant *Klebsiella pneumoniae* expressing the *bla*_{OXa-232} gene during an institutional outbreak associated

Page 8 of 8

with endoscopic retrograde cholangiopancreatography. Clin Infect Dis. 2017;64:894–901.

- Enne VI, Bennett PM, Livermore DM, Hall LM. Enhancement of host fitness by the *sul2*-encoding plasmid p9123 in the absence of selective pressure. J Antimicrob Chemother. 2004;53:958–63.
- Dionisio F, Conceição IC, Marques AC, Fernandes L, Gordo I. The evolution of a conjugative plasmid and its ability to increase bacterial fitness. Biol Lett. 2005;1:250–2.
- Humphrey B, Thomson NR, Thomas CM, Brooks K, Sanders M, Delsol AA, et al. Fitness of *Escherichia coli* strains carrying expressed and partially silent IncN and IncP1 plasmids. BMC Microbiol. 2012;12:53.
- Mei Y, Liu P, Wang LG, Liu Y, Wang LH, Wei DD, et al. Virulence and genomic feature of a virulent *Klebsiella pneumoniae* sequence type 14 strain of serotype K2 harboring *bla*_{NDM-5} in China. Front Microbiol. 2017;8:335.
- Buckner MMC, Saw HTH, Osagie RN, McNally A, Ricci V, Wand ME, et al. Clinically relevant plasmid-host interactions indicate that transcriptional and not genomic modifications ameliorate fitness costs of *Klebsiella pneumoniae* carbapenemase-carrying plasmids. mBio. 2018;9:e02303–17.
- Wu R, Yi L, Yu LF, Wang J, Liu Y, Chen X, et al. Fitness advantage of mcr-1bearing Incl2 and IncX4 plasmids in vitro. Front Microbiol. 2018;9:331.
- San Millan A, Toll-Riera M, Qi Q, MacLean RC. Interactions between horizontally acquired genes create a fitness cost in *Pseudomonas* aeruginosa. Nat Commun. 2015;6:6845.
- San Millan A, Toll-Riera M, Qi Q, Betts A, Hopkinson RJ, McCullagh J, MacLean RC. Integrative analysis of fitness and metabolic effects of plasmids in *Pseudomonas aeruginosa* PAO1. ISME J. 2018;12:3014–24.
- 34. Carroll AC, Wong A. Plasmid persistence: costs, benefits, and the plasmid paradox. Can J Microbiol. 2018;64:293–304.
- Both A, Huang J, Kaase M, Hezel J, Wertheimer D, Fenner I, et al. First report of *Escherichia coli* co-producing NDM-1 and OXA-232. Diagn Microbiol Infect Dis. 2016;86:437–8.
- Avolio M, Vignaroli C, Crapis M, Camporese A. Co-production of NDM-1 and OXA-232 by ST16 *Klebsiella pneumoniae*, Italy, 2016. Future Microbiol. 2017; 12:1119–22.
- 37. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–8.
- Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*: a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873–84.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

